Hemophilia B Clinical Trials

197 clinical trials for Hemophilia B across international registries, including 39 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B — RECRUITING · PHASE3
• Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) — RECRUITING · PHASE3
• A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B — RECRUITING · PHASE1
• Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B — RECRUITING · PHASE3
• A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency) — RECRUITING · PHASE1
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors — RECRUITING · PHASE3
• An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency — RECRUITING · PHASE1
• Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively — RECRUITING · PHASE3
• Synovial Proliferation on Routine Ultrasound: Active or Inactive? — RECRUITING
• Lentiviral FIX Gene Therapy — RECRUITING · PHASE1
• Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders — RECRUITING
• ATHNdataset Registry — RECRUITING
• An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B — RECRUITING
• Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies. — RECRUITING · PHASE3
• National Longitudinal Cohort of Hematological Diseases — RECRUITING
• An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B — RECRUITING · PHASE3
• AN OPEN-LABEL, PARALLEL, PHASE 3, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED 1 TO LESS THAN 12 YEARS WITH HEMOPHILIA A OR B WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTORS VIII OR IX — RECRUITING · PHASE3
• Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222) — RECRUITING
• Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN) — RECRUITING · PHASE1
• The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients. — RECRUITING · NA
• A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients — RECRUITING · PHASE1
• Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old — RECRUITING · PHASE1
• Measurement Properties in People with Hemophilia — RECRUITING · NA
• Longitudinal Cohort of Thrombosis and Hemostasis Diseases — RECRUITING
• A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9-BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B — RECRUITING
• PHASE 3B, OPEN-LABEL, MULTICENTER, SINGLE-DOSE STUDY INVESTIGATING EFFICACY AND SAFETY OF CSL222 (ETRANACOGENE DEZAPARVOVEC) GENE THERAPY ADMINISTERED TO ADULT SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B WITH DETECTABLE PRETREATMENT AAV5 NEUTRALIZING ANTIBODIES — RECRUITING · PHASE3
• World Bleeding Disorders Registry — RECRUITING
• A GLOBAL, OPEN-LABEL, ADAPTIVE DESIGN STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SERPINPC IN SUBJECTS WITH SEVERE HEMOPHILIA A OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B — RECRUITING
• German Pediatric Hemophilia Research Database — RECRUITING
• A PHASE 3, SINGLE-ARM, MULTICENTER, MULTINATIONAL, OPEN-LABEL, ONE-WAY CROSSOVER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED >/= 12 YEARS WITH SEVERE HEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTOR VIII OR IX — RECRUITING · PHASE3
• AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A PARTICIPANTS WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY <=2%) WITH OR WITHOUT INHIBITORS — RECRUITING
• OPEN-LABEL STUDY INVESTIGATING EFFICACY, SAFETY AND PHARMACOKINETICS OF CONCIZUMAB PROPHYLAXIS IN CHILDREN BELOW 12 YEARS WITH HAEMOPHILIA A OR B WITH OR WITHOUT INHIBITORS — RECRUITING
• PHASE 3, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF-06838435 (RAAV-SPARK100-HFIX-PADUA) IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B (FIX:C¿2%) (BENEGENE-2) — RECRUITING · PHASE3
• EFFICACY AND SAFETY OF CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A OR B WITHOUT INHIBITORS — RECRUITING
• A NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY (PASS) IN MALE HAEMOPHILIA B PATIENTS RECEIVING NONACOG BETA PEGOL (N9-GP) PROPHYLAXIS TREATMENT — RECRUITING
• ATLAS-PPX: AN OPEN-LABEL, MULTINATIONAL, SWITCHING STUDY TO DESCRIBE THE EFFICACY AND SAFETY OF FITUSIRAN PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A AND B PREVIOUSLY RECEIVING FACTOR OR BYPASSING AGENT PROPHYLAXIS. — RECRUITING
• GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 [ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE] IN SUBJECTS WITH HEMOPHILIA B — RECRUITING
• GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 (ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE) IN SUBJECTS WITH HEMOPHILIA B — RECRUITING
• AN OPEN-LABEL SINGLE-ARM MULTICENTRE NON-CONTROLLED PHASE 3A TRIAL INVESTIGATING SAFETY AND NONACOG BETA PEGOL (N9-GP) IN PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY UNTREATED PATIENTS WITH HAEMOPHILIA B — RECRUITING · PHASE3
• Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B — COMPLETED · PHASE3
• Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX — TERMINATED
• Liver Biopsy Following Gene Therapy For Hemophilia — NOT_YET_RECRUITING
• Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B — COMPLETED · PHASE2
• A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy — ACTIVE_NOT_RECRUITING
• Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B — TERMINATED · PHASE1
• Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy — COMPLETED · PHASE3
• A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/CAS9-Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B — TERMINATED · PHASE2
• Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B — TERMINATED · PHASE3
• Early Check: Expanded Screening in Newborns — ACTIVE_NOT_RECRUITING
• BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B — TERMINATED · PHASE1

Refine this search